Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. (Q43640246)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Vittorio Montefusco

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jesús San Miguel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Niels W C J van de Donk

1

object named as

van de Donk NW

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

15

Lokhorst HM

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Kröger N

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hegenbart U

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Goldschmidt H

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Perez-Simon JA

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Zijlmans M

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Raymakers RA

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ayuk FA

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

van Oers MH

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Nagler A

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Verdonck LF

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1135-1141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16757975%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705393

29 January 2020

exact match

0 references

cites work

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Autologous and allogeneic stem cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Bone-marrow transplantation (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705393

7 January 2021